Switzerland
Roche joins race to halt Alzheimer’s progression
Roche is testing a treatment to see whether it can halt the progression of Alzheimer’s disease. A participant in the Swiss drugmaker’s trial says the monitoring has reassured her as she lives with the condition.

Roche is testing whether a new drug can slow Alzheimer’s progression, and one participant says the trial’s close monitoring has helped her face the disease. Carole Greig, a 71-year-old former bank employee, noticed problems with her short-term memory while working as a companion to women with dementia. Doctors diagnosed her with Alzheimer’s in 2023. This year, she joined a late-stage Roche trial of trontinemab, which is designed to clear amyloid plaques in the brain.
Greig says confusion, anxiety and difficulties organising tasks are among the problems she experiences. The trial has given her regular contact with clinicians as well as access to an experimental treatment. “It’s one of the best decisions I’ve ever made,” she said. Roche is enrolling more than 1,000 patients in the study. Its first results are expected in 2028. The company is among drugmakers, including Eli Lilly, testing whether treatments can do more than modestly slow cognitive decline. Roche’s trial focuses on people already living with Alzheimer’s, while the broader research push also aims to prevent symptoms emerging.
Carry the treatment into the brain
Trontinemab is engineered to carry its antibody payload across the brain’s protective barrier. The blood-brain barrier blocks harmful substances from entering the central nervous system, but it also makes it difficult for Alzheimer’s drugs to reach their target. Catherine Mummery, chief investigator for Roche’s trial at London’s National Hospital for Neurology and Neurosurgery, said only about 0.1% of existing monoclonal antibody drugs penetrate the barrier.
Roche’s Brainshuttle technology attaches the anti-amyloid antibody to receptors that transport iron into the brain. That binding is intended to help the drug cross the barrier in a controlled way. Mummery said the mechanism prevents the drug from “diffusing into the brain” uncontrolled and “distributes it much more evenly”. The approach addresses a practical problem with existing treatments: because little of the medicine reaches the brain, patients receive high doses. Those doses can bring serious risks, including brain swelling and bleeding. Trontinemab is given through a drip, and Roche is testing whether its delivery design can improve the drug’s reach while clearing amyloid plaques.
Put the early results to the test
Early results suggest trontinemab can clear amyloid plaques quickly, but Roche’s late-stage trial will test whether that changes the course of illness. In an earlier study, plaque levels fell below detectable limits in nine out of 10 patients after 28 weeks. The build-up that the drug removed typically takes 15 to 20 years to form, according to the report.
That finding has encouraged Roche to move into larger studies. It does not yet establish that patients will retain their cognitive abilities or that the disease can be halted. Existing Alzheimer’s drugs have modestly slowed progression, but have not halted or reversed it. Roche’s global head of neurodegeneration, Geoffrey Kerchner, said success would mean steering patients towards “a substantially slower rate of disease worsening”. The distinction matters for participants such as Greig, who is living with symptoms while clinicians monitor her during the trial. Results due in 2028 will provide a major test of whether the new delivery method and plaque clearance can translate into a meaningful change for patients.
Track the growing dementia burden
The pressure to find better treatments is growing as dementia affects tens of millions of people worldwide. Alzheimer’s is the most common form of dementia. Alzheimer’s Disease International counted more than 55 million people living with dementia in 2020 and projects 139 million by 2050, with the total expected to almost double every 20 years.
For Switzerland, Roche’s work sits alongside a difficult treatment landscape. In February 2026, Swissmedic was expected to approve two Alzheimer’s drugs, but approved only one. The developments underline how closely patients and clinicians follow progress in treatment research. Greig says being kept informed and monitored during her participation has reassured her. The next milestone for Roche’s programme is the late-stage trial’s first results in 2028. The study is testing whether trontinemab can slow the worsening of Alzheimer’s in people already diagnosed, while Roche and other companies also pursue research aimed at delaying or preventing symptoms. For patients and families, the trial brings a new option to investigate, with its impact to be judged by the results.